Pfizer Corporation

Other

Neurogen Corporation

Pfizer Products Inc.

Pfizer, Inc. Patent Department

Marlys Hammond

Richard Louis Elliott

Alan J Hutchison

Charles A Blum

Richard F Hank

Jun Yuan

Andrew Y Thurkauf

Robert L Dow

David Andrew Griffith

Kimberly O Cameron

Xiaozhang Zheng

Philip Albert Carpino

Rajagopal Bakthavatchalam

Jennifer N Tran

James William Darrow

Harry Brielmann

St&eacute;phane De Lombaert

Richard L Elliot

This invention relates to CCK-A agonists of Formula (I) wherein R-R, A, B, X, D, E and G are as defined in the specification, as well as, among other things, pharmaceutical compositions containing the compounds and methods of use of the compounds and compositions. The compounds are useful in treating diabetes.

Tetraazabenzo[e]azulene derivatives and analogs thereof

Compounds of Formula (I) that act as cannabinoid receptor ligands and their uses in the treatment of diseases linked to the mediation of the cannabinoid receptors in animals are described herein 

Cannabinoid receptor ligands and uses thereof

This invention relates to CCK-A agonists of Formula (I) wherein R-R, A, B, X, D, E and G are as defined in the specificiation, as well as, among other things, pharmaceutical compositions containing the compounds and methods of use of the compounds and compositions. The compounds are useful in treating obesity.

Compounds of Formula (I) that act as cannabinoid receptor ligands and their uses in the treatment diseases, conditions and/or disorders herein. 

The present invention provides NPY-5 receptor antagonists having a Formula (I)Methods and pharmaceutical compositions useful for treating diseases, conditions and/or disorders modulated by the above NPY-5 receptor antagonists are also provided.

Aminophenanthridinone and aminophenanthridine as NPY-5 antagonists

Substituted spiro&lsqb;isobenzofuran-1,4&prime;-piperidin&rsqb;-3-ones and 3H-spiroisobenzofuran-1,4&prime;-piperidines capable of modulating NPY5 receptor activity are provided. Such compounds may be used to modulate ligand binding to NPY5 receptors in vivo or in vitro, and are particularly useful in the treatment of a variety of disorders (e.g., eating disorders such as obesity or bulimia, psychiatric disorders, diabetes and cardiovascular disorders such as hypertension) in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and methods for treating such disorders are provided, as are methods for using such compounds for detecting NPY5 receptors.

Spiro&lsqb;isobenzofuran-1,4&prime;-piperidin&rsqb;-3-ones and 3H-spiroisobenzofuran-1,4&prime;-piperidines

NPY antagonists, methods of using such NPY antagonists and pharmaceutical compositions containing such NPY antagonists. The NPY antagonists are useful for the treatment of NPY mediated disease/conditions including obesity.

Compounds for the treatment of obesity

Certain diaryl imidazoles act as partial agonists or antagonists for NPY receptors, in particular NPY 5 receptors. They are of use, for example in treating loss of appetite. Such compounds bear aryl groups in the 2 position. Many of the compounds are novel.

Pharmaceutical compositions containing certain diarylimidazole derivatives

Neuropeptide Y antagonists

Carbazole neuropeptide Y5 antagonists

Neuropeptide antagonists

This invention provides a means of inhibiting or preventing a disease or condition associated with an excess of neuropeptide Y which comprises administering to a mammal in need of such treatment an effective amount of a compound of the formula:

Growing community of inventors

Salem, CT, United States of America

Marlys Hammond